Pegvisomant
Also known as: Somavert
Key Facts: Pegvisomant
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Acromegaly
- Administration
- Subcutaneous injection daily
- Typical Dose
- 10-30 mg daily
- Frequency
- Once daily
- Duration
- Long-term / chronic use
Mechanism of Action
Pegvisomant is a modified GH analog that binds GH receptors but prevents receptor activation and signaling. It directly blocks GH action rather than suppressing GH secretion, effectively normalizing IGF-1 levels.
Research Summary
Most effective medical therapy for normalizing IGF-1 in acromegaly (~90% achieve normal IGF-1). Does not shrink tumors. Often combined with somatostatin analogs. PEGylation extends half-life for daily dosing.
Dosing Information
Typical Dosingⓘ
Community experience
10-30 mg daily
10-40 mg daily
Once daily
GH receptor antagonist for acromegaly. Prescription only. Requires monitoring of liver function.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
40 mg loading dose
10-30 mg daily maintenance
Duration
Long-term / chronic use
Administration
Subcutaneous injection daily
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Infection
- ●Pain
- ●Nausea
- ●Injection site reactions
- ●Liver toxicity (rare but serious)
- ●Hypoglycemia in diabetics
- ●FDA approved (Somavert)
References
- https://pubmed.ncbi.nlm.nih.gov/11018015/
- https://pubmed.ncbi.nlm.nih.gov/15141043/
- https://pubmed.ncbi.nlm.nih.gov/22058377/
Research This Peptide Further
Frequently Asked Questions
What does Pegvisomant do?
A GH receptor antagonist that blocks growth hormone action. Used for acromegaly when surgery and somatostatin analogs fail to normalize IGF-1.
How does Pegvisomant work?
Pegvisomant is a modified GH analog that binds GH receptors but prevents receptor activation and signaling. It directly blocks GH action rather than suppressing GH secretion, effectively normalizing IGF-1 levels.
Is Pegvisomant FDA approved?
Yes, Pegvisomant is FDA approved. FDA Approved - Acromegaly
What are the side effects of Pegvisomant?
Reported side effects include: Infection, Pain, Nausea, Injection site reactions, Liver toxicity (rare but serious). Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Pegvisomant?
Community-reported common dose: 10-30 mg daily (Once daily). Range: 10-40 mg daily. Administration: Subcutaneous injection daily. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Pegvisomant or used in similar applications.
Gonadorelin
FDAA synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.
HormonalLanreotide
FDAA long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.
HormonalMacimorelin
FDAAn oral ghrelin mimetic used to diagnose adult growth hormone deficiency. The first FDA-approved oral GH stimulation test.
HormonalOxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalLeuprolide
FDAA GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
HormonalDesmopressin
FDAA synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.
HormonalWant updates on Pegvisomant research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.